Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Concerning Reversal of Allowance for Doubtful Accounts of Subsidiaries and Affiliates in Company’s Non-consolidated Financial Statements
Sumitomo Pharma Announces Revisions to Its Financial Forecasts and Recording of Gains from Transfer of Equity Interests
Sumitomo Pharma, Last Fiscal Year Net Income Revised Upward by 48%
Sumitomo Pharma Announces Reduction in Executive Remuneration
Notice Regarding a Company Split of the Asian Business and the Execution of a Share Transfer Agreement and a Shareholders’Agreement
Notice of Transition to Company with an Audit & Supervisory Committee
Notice Regarding Refinancing of Existing Borrowings Through a Syndicated Loan
Notice of Capital Reorganization within Sumitomo Pharma Group
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2025
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2025 [IFRS]
Conference on Q3 FY2024 (April 1, 2024 to December 31, 2024) Financial Results
Sumitomo Pharma Announces Revisions to Its Financial Forecasts
Notice Concerning Finance Income
Sumitomo Pharma, The Current Fiscal Year Net Income Turns to Profit, Exceeds Expectations
Sumitomo Pharma Announces Agreement on Co-Promotion Collaboration Partner for Marketing of PPLAT XEPLION and XEPLION TRI in Japan
Sumitomo Pharma Co., Ltd., July-September (2Q) Net Income Loss Widens
Sumitomo Pharma Announces the Results of Its Early Retirement Program Offer to Employees in Japan for Business Structural Reform
Notice Concerning Finance Costs
Conference on Q2 FY2024 (April 1, 2024 to September 30, 2024) Financial Results
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2025